Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: Evidence of auto-induction of gemcitabine accumulation

Journal of Clinical Oncology

Volumn 25, Issue 36, 2007, Pages 5704-5709

  Grimison, Peter ^a   Galettis, Peter ^a   Manners, Susan ^a   Jelinek, Maria ^a   Metharom, Ekkaphon ^a   de Souza, Paul L ^a   Liauw, Winston ^a   Links, Matthew J ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIFLUORODEOXYURIDINE; FLOXURIDINE DERIVATIVE; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; HEPATOBILIARY SYSTEM CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFUSION RATE; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS;

EID: 37649000783     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.10.7078     Document Type: Article

References (19)

1. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
2. Shepherd FA, Burkes R, Cormier Y, et al: Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose. J Clin Oncol 14:1656-1662, 1996
3. Plunkett W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23:3-15, 1996 (5 suppl 10)
4. Grunewald R, Kantarjian H, Du M, et al: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
5. Shord SS, Faucette SR, Gillenwater HH, et al: Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51:328-336, 2003
6. Tempero M, Plunkett W, Ruiz Van Haperen V, et al: Randomized phase II comparison of doseintense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408, 2003
7. Poplin E, Levy DE, Berlin J, et al: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24:LBA4004, 2006
8. Freeman KB, Anliker S, Hamilton M, et al: Validated assays for the determination of gemcitabine in human plasma and urine using highperformance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 665:171-181, 1995
9. Cappuzzo F, Novello S, De Marinis F, et al: A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer 52:319-325, 2006
10. Ceribelli A, Gridelli C, De Marinis F, et al: Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: A randomized phase II study of two different schedules in combination with cisplatin. Cancer 98:337-343, 2003
11. Soo RA, Wang LZ, Tham LS, et al: A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17:1128-1133, 2006
12. Liebes L, Levy DE, Poplin E, et al: Gemcitabine (G) plasma and intracellular pharmacokinetics in E6201: Greater metabolite levels using fixed dosing rate (FDR) delivery. J Clin Oncol 24:2024, 2006
13. Csapo Z, Sasvari-Szekely M, Spasokoukotskaja T, et al: Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem Pharmacol 61:191-197, 2001
14. Kong XB, Tong WP, Chou TC: Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Mol Pharmacol 39:250-257, 1991
15. Kroep JR, Loves WJ, van der Wilt CL, et al: Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1:371-376, 2002
16. Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-1325, 2004
17. Bepler G, Zheng Z, Gautam A, et al: Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47:183-192, 2005
18. Shi JY, Shi ZZ, Zhang SJ, et al: Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14:759-768, 2004
19. Yue L, Saikawa Y, Ota K, et al: A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13:29-38, 2003